X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (917) 917
Book Review (137) 137
Publication (17) 17
Conference Proceeding (8) 8
Dissertation (7) 7
Paper (3) 3
Magazine Article (2) 2
Trade Publication Article (2) 2
Book Chapter (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olmesartan medoxomil (699) 699
index medicus (572) 572
humans (437) 437
hypertension (348) 348
male (330) 330
hypertension - drug therapy (311) 311
pharmacology & pharmacy (243) 243
tetrazoles - therapeutic use (240) 240
imidazoles - therapeutic use (235) 235
female (226) 226
blood pressure - drug effects (223) 223
antihypertensive agents - therapeutic use (212) 212
animals (182) 182
middle aged (177) 177
peripheral vascular disease (158) 158
aged (147) 147
drug therapy, combination (145) 145
tetrazoles - pharmacology (145) 145
imidazoles - pharmacology (141) 141
hydrochlorothiazide (140) 140
treatment outcome (137) 137
angiotensin ii type 1 receptor blockers - therapeutic use (135) 135
tetrazoles - administration & dosage (135) 135
antihypertensive agents - administration & dosage (130) 130
antihypertensive agents - adverse effects (130) 130
imidazoles - administration & dosage (129) 129
tetrazoles - adverse effects (128) 128
imidazoles - adverse effects (125) 125
hypertension - physiopathology (124) 124
adult (119) 119
olmesartan (115) 115
blood-pressure (114) 114
amlodipine (113) 113
rats (110) 110
azilsartan medoxomil (101) 101
blood pressure (101) 101
double-blind (100) 100
medoxomil (95) 95
double-blind method (91) 91
medicine & public health (87) 87
dose-response relationship, drug (84) 84
drug therapy (84) 84
antihypertensive agents - pharmacology (79) 79
drug combinations (78) 78
angiotensin (77) 77
pharmacology/toxicology (76) 76
efficacy (75) 75
valsartan (75) 75
internal medicine (73) 73
dosage and administration (70) 70
pharmacotherapy (70) 70
amlodipine besylate (69) 69
angiotensin ii type 1 receptor blockers - pharmacology (69) 69
angiotensin ii type 1 receptor blockers - adverse effects (67) 67
angiotensin receptor antagonists (67) 67
cardiac & cardiovascular systems (67) 67
research (67) 67
angiotensin ii type 1 receptor blockers - administration & dosage (66) 66
pharmacokinetics (64) 64
management (60) 60
hydrochlorothiazide - administration & dosage (59) 59
amlodipine - administration & dosage (57) 57
amlodipine - therapeutic use (57) 57
hydrochlorothiazide - therapeutic use (57) 57
time factors (57) 57
tetrazoles - pharmacokinetics (55) 55
benzimidazoles - therapeutic use (54) 54
combination therapy (54) 54
imidazoles - pharmacokinetics (54) 54
prospective studies (53) 53
losartan (52) 52
combination (51) 51
safety (47) 47
antihypertensive agents - pharmacokinetics (46) 46
blood pressure monitoring, ambulatory (46) 46
chemistry, analytical (46) 46
angiotensin receptor blocker (43) 43
calcium channel blockers - therapeutic use (43) 43
amlodipine - adverse effects (42) 42
analysis (42) 42
blood pressure - physiology (41) 41
hydrochlorothiazide - adverse effects (41) 41
hypertension - complications (41) 41
angiotensin ii (40) 40
randomized controlled trials as topic (40) 40
tablets (40) 40
aged, 80 and over (39) 39
cardiology (38) 38
disease models, animal (38) 38
therapy (38) 38
drugs (37) 37
risk factors (37) 37
renin-angiotensin system - drug effects (36) 36
angiotensin-converting enzyme inhibitors - therapeutic use (35) 35
chlorthalidone (35) 35
antihypertensive drugs (34) 34
care and treatment (34) 34
mice (34) 34
oxidative stress (34) 34
administration, oral (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (866) 866
Russian (21) 21
German (14) 14
Spanish (8) 8
Japanese (7) 7
Chinese (6) 6
French (6) 6
Croatian (1) 1
Dutch (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Regulatory Toxicology and Pharmacology, ISSN 0273-2300, 12/2016, Volume 82, pp. 20 - 31
Poor aqueous solubility and unfavourable de-esterification of olmesartan medoxomil (a selective angiotensin II receptor blocker), results in low oral... 
Olmesartan nanoemulsion | Brain penetration | Tissue distribution | Sub-chronic toxicity | Hematological parameters | Histopathological characteristics | MEDICINE, LEGAL | RATS | FORMULATION | HYPERTENSIVE PATIENTS | BIOAVAILABILITY | STROKE | PHARMACOKINETICS | DISEASE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ABSORPTION | ORGAN WEIGHT | BRAIN | Emulsions | Olmesartan Medoxomil - pharmacokinetics | Rats, Wistar | Antihypertensive Agents - administration & dosage | Body Weight - drug effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Olmesartan Medoxomil - chemistry | Drug Carriers | Brain - metabolism | Nanoparticles | Tissue Distribution | Tandem Mass Spectrometry | Antihypertensive Agents - toxicity | Olmesartan Medoxomil - toxicity | Water - chemistry | Chromatography, Liquid | Drug Compounding | Oils - chemistry | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Olmesartan Medoxomil - administration & dosage | Reproducibility of Results | Angiotensin II Type 1 Receptor Blockers - chemistry | Risk Assessment | Administration, Oral | Toxicity Tests, Subchronic | Antihypertensive Agents - pharmacokinetics | Biomarkers - blood | Permeability | Antihypertensive Agents - chemistry | Eating - drug effects | Organ Size - drug effects | Animals | Nanomedicine - methods | Drinking - drug effects | Angiotensin II Type 1 Receptor Blockers - toxicity | Stroke (Disease) | Medical colleges | Safety and security measures | Air bases | Pharmacy | Angiotensin | Drugstores | Comparative analysis | Index Medicus
Journal Article
INTERNATIONAL JOURNAL OF NANOMEDICINE, ISSN 1178-2013, 2019, Volume 14, pp. 1953 - 1968
Journal Article
Journal Article
Journal Article
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 06/2015, Volume 9, pp. 2811 - 2817
A fixed-dose combination of amlodipine and olmesartan is used to treat high blood pressure in patients whose hypertension is not sufficiently controlled with... 
Amlodipine besylate | Bioequivalence | Fixed-dose combination | Amlodipine orotate | Olmesartan medoxomil | amlodipine orotate | MULTICENTER | CHEMISTRY, MEDICINAL | SAFETY | PHASE-III | olmesartan medoxomil | ADULT KOREAN PATIENTS | MEDOXOMIL | fixed-dose combination | amlodipine besylate | PHARMACOKINETICS | PARALLEL-GROUP | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | 8-WEEK | TO-MODERATE HYPERTENSION | bioequivalence | Salts | Area Under Curve | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Antihypertensive Agents - pharmacokinetics | Amlodipine Besylate, Olmesartan Medoxomil Drug Combination - administration & dosage | Cross-Over Studies | Young Adult | Antihypertensive Agents - chemistry | Amlodipine Besylate, Olmesartan Medoxomil Drug Combination - pharmacokinetics | Amlodipine Besylate, Olmesartan Medoxomil Drug Combination - chemistry | Adult | Female | Therapeutic Equivalency | Dose-response relationship (Biochemistry) | Amlodipine | Dosage and administration | Models | Drug therapy, Combination | Methods | Hypertension | Urine | EKG | Physical examinations | Clinical trials | Smooth muscle | Chromatography | Laboratory tests | Confidence intervals | Hospitals | Metabolites | Electrocardiography | Blood pressure | Adults | Safety | Acceptance criteria | Drug dosages | Index Medicus
Journal Article
The Journal of Clinical Hypertension, ISSN 1524-6175, 09/2017, Volume 19, Issue 9, pp. 874 - 883
This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone ( AZL ‐M/ CLD... 
chlorthalidone | fixed‐dose combination | angiotensin receptor blocker | diuretic | azilsartan | fixed-dose combination | MANAGEMENT | REDUCING CARDIOVASCULAR EVENTS | RECEPTOR BLOCKERS | MEDOXOMIL | BLOOD-PRESSURE | HYDROCHLOROTHIAZIDE | SERUM CREATININE | THERAPY | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Oxadiazoles - administration & dosage | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Essential Hypertension - drug therapy | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Olmesartan Medoxomil - therapeutic use | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Chlorthalidone - therapeutic use | Essential Hypertension - classification | Olmesartan Medoxomil - administration & dosage | Olmesartan Medoxomil - adverse effects | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - therapeutic use | Oxadiazoles - therapeutic use | Oxadiazoles - adverse effects | Chlorthalidone - administration & dosage | Diuretics - therapeutic use | Aged | Hydrochlorothiazide - therapeutic use | Hypertension | Dosage and administration | Chlorthalidone | Drug therapy, Combination | Comparative analysis | Index Medicus
Journal Article
Journal Article
Acta poloniae pharmaceutica, ISSN 0001-6837, 03/2016, Volume 73, Issue 2, pp. 509 - 516
Combination therapy with diuretics and angiotensin II type I (ATI) receptor antagonist is frequently recommended for the control of blood pressure in... 
Hydrochlorothiazide | Bioequivalence | Pharmacokinetics | Olmesartan medoxomil | Combination tablet | TRIALS | METAANALYSIS | HUMAN PLASMA | RISK | binequivalence | BLOOD-PRESSURE | MASS-SPECTROMETRY | THERAPY | hydrochlorothiazide | olmesanan medoxomil | PHARMACOLOGY & PHARMACY | COHORT | combination tablet | HYPERTENSION | phannacokinetics | Hydrochlorothiazide - pharmacokinetics | Olmesartan Medoxomil - pharmacokinetics | Tablets | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Biological Availability | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Young Adult | Tandem Mass Spectrometry | Drugs, Generic - pharmacokinetics | Sodium Chloride Symporter Inhibitors - administration & dosage | Chromatography, Liquid | Adult | Hydrochlorothiazide - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Olmesartan Medoxomil - blood | Olmesartan Medoxomil - administration & dosage | Sodium Chloride Symporter Inhibitors - pharmacokinetics | Administration, Oral | Drugs, Generic - administration & dosage | Hydrochlorothiazide - administration & dosage | Sodium Chloride Symporter Inhibitors - blood | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Therapeutic Equivalency | Index Medicus
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 08/2016, Volume 10, pp. 2599 - 2609
The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety... 
Hypertension | Rosuvastatin | Olmesartan medoxomil | Dyslipidemia | Fixed-dose combination therapy | fixed-dose combination therapy | POPULATION | OXIDATIVE STRESS | ATHEROGENESIS | CHEMISTRY, MEDICINAL | ENDOTHELIAL DYSFUNCTION | olmesartan medoxomil | RISK | OPEN-LABEL | PREVALENCE | AT1-TYPE ANGIOTENSIN RECEPTOR | STATINS | BLOOD-PRESSURE | PHARMACOLOGY & PHARMACY | dyslipidemia | rosuvastatin | hypertension | Dyslipidemias - drug therapy | Olmesartan Medoxomil - administration & dosage | Rosuvastatin Calcium - therapeutic use | Double-Blind Method | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Olmesartan Medoxomil - adverse effects | Antihypertensive Agents - therapeutic use | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Olmesartan Medoxomil - therapeutic use | Female | Drug Combinations | Republic of Korea | Dyslipidemias | Patient outcomes | Drug therapy, Combination | Drug therapy | Methods | Heart | Drugs | Therapy | Oxidative stress | Compliance | Laboratories | Angioplasty | Lipids | Cardiovascular disease | Standard error | Family medical history | Density | Confidence intervals | Randomization | Safety engineering | Blood pressure | Safety | Cardiology | Drug dosages | Statins | Internal medicine | Cholesterol | Medicine | Side effects | Lipoproteins | Hospitals | Least squares | Lifestyles | Diabetes | Clinical medicine | Index Medicus | Fixed-dose Combination Therapy
Journal Article
Journal of International Pharmaceutical Research, ISSN 1674-0440, 2018, Volume 45, pp. 49 - 68
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2017, Volume 39, Issue 7, pp. 1371 - 1379
Abstract Purpose A fixed-dose combination (FDC) pill of amlodipine (relatively old calcium channel blocker as dihydropyridine) and olmesartan (relatively new... 
Internal Medicine | Medical Education | pharmacokinetics | S-amlodipine | olmesartan | bioequivalence | EFFICACY | DOUBLE-BLIND | BESYLATE | PHARMACOLOGY & PHARMACY | Olmesartan Medoxomil - pharmacokinetics | Tablets | Humans | Male | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Niacin - administration & dosage | Young Adult | Amlodipine - pharmacokinetics | Adult | Amlodipine - administration & dosage | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Niacin - blood | Olmesartan Medoxomil - blood | Olmesartan Medoxomil - administration & dosage | Amlodipine - blood | Cross-Over Studies | Asian Continental Ancestry Group | Calcium Channel Blockers - administration & dosage | Niacin - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Calcium Channel Blockers - blood | Calcium Channel Blockers - pharmacokinetics | Drug Combinations | Therapeutic Equivalency | Hypertension | Calcium channels | Analysis | Amlodipine | Dosage and administration | Drug therapy, Combination | Patient compliance | Drugs | Physical examinations | Calcium | Laboratories | Males | Ethics | Mathematical analysis | New combinations | Blood pressure | Safety | Dihydropyridine | Angiotensin II | Product safety | Drug dosages | Formulations | Urine | Test procedures | Data processing | Pharmacology | Bioavailability | Patients | Variance analysis | Hypotension | Angiotensin | Clinical medicine | Index Medicus
Journal Article